Woojin B&G Targets Asian Aquaculture Vaccine Market with Launch of Local Clinical Trials in Indonesia

Woojin B&G has begun local clinical trials for its iridovirus prevention vaccine in Indonesia, marking a full-scale entry into the Asian aquaculture vaccine market. Targeting the Asian iridovirus vaccine market, which is estimated to be worth around 100 billion won, the company plans to accelerate the establishment of regulatory approvals and export infrastructure.

On the 27th, Woojin B&G announced that it has launched on-site clinical trials at a marine cage farm in Bali to obtain product approval and promote local sales of its self-developed iridovirus prevention vaccine, IMMUNIS® MEGAVAC, in Indonesia.

This is the first clinical trial to be conducted locally in Indonesia for a fish vaccine that was developed and commercialized in Korea, as part of the country's approval process. Gadjah Mada University (UGM) is at the center of the trial, working together with local aquaculture companies and farm officials. The trial aims to comprehensively verify the safety and preventive efficacy of the vaccine on major farmed fish species vulnerable to iridovirus and to secure the data needed for regulatory approval.

Based on these clinical trials, Woojin B&G has set a goal to obtain product approval in Indonesia by 2028. The company also plans to build distribution networks and conduct marketing activities concurrently, with the official local launch of the product targeted for 2029.

Asia is the world's largest aquaculture production region, and iridovirus outbreaks in high-value fish such as groupers and barramundi are considered a key factor undermining the profitability of the aquaculture industry. In particular, Indonesia has a high proportion of high-value fish species that are vulnerable to the virus, making it a critical bridgehead for entry into the Southeast Asian market.

IMMUNIS MEGAVAC is a product whose efficacy has already been proven in Korea. Since its first introduction in 2022 at major fish farms in Tongyeong and Geoje, it was administered to more than 3 million striped beakfish in 2025 alone, with total vaccinations soon reaching 10 million fish. Field trials in Korea showed an average survival rate exceeding 80% among vaccinated fish, drawing high interest from the Indonesian aquaculture community as well.

An Indonesian aquaculture official who attended Woojin B&G's local workshop explained, "Earlier this year, a barramundi farm suffered total stock losses due to iridovirus and complex infections, highlighting how severe the local impact is. We hope that a vaccine proven effective in Korean fish farms will demonstrate superior protective effects in Indonesia, too."

A Woojin B&G official stated, "The Indonesian clinical trial and product approval process will be a strategic base for preempting the Asian iridovirus vaccine market, estimated at about 100 billion won. We are committed to successfully completing the clinical trials, expanding exports throughout Southeast Asia, and establishing a global business model for K-aquaculture vaccines."

This local clinical trial in Indonesia is considered a significant turning point in expanding Woojin B&G’s global aquaculture vaccine business, as it marks the company’s first step in obtaining overseas regulatory approval to gain a foothold in the Asian iridovirus vaccine market.

This content was produced with the assistance of AI translation services.